Conceptio › Archive › ClinicalTrials.gov
ClinicalTrials.govpublic full text

The Immunogenicity and Safety Following a Heterologous Booster Dose of Recombinant SARS-CoV-2 Vaccine LYB001

Guangzhou Patronus Biotech Co., Ltd. · 2022
ClinicalTrials.gov · Datasets · License: Public Domain · 2022
Open Source ↗
covearlyimmunogenicitysafety
covid-19, vaccine reaction, safety, immunogenicity, heterologous booster, inactivated covid-19 vaccine, recombinant sars-cov-2 vaccine, interventional, early_phase1
This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Related documents

Record · ID 874280
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.